Live Nasdaq Composite: Stocks Slip as Oil Climbs, Big Tech Earnings Take Spotlight

Investing

Novo Nordisk : NVO

All Novo Nordisk Articles

169 Articles

Vandita Jadeja | May 21, 2026 at 8:25 AM EDT

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5%…

Alex Sirois | May 18, 2026 at 1:55 PM EDT

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious:…

David Moadel | May 5, 2026 at 10:44 AM EDT

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street. Barclays analyst Emily Field raised her…

Thomas Richmond | Apr 30, 2026 at 8:05 PM EDT

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO |…

David Moadel | Apr 24, 2026 at 12:01 PM EDT

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight…

Ian Cooper | Apr 22, 2026 at 12:24 PM EDT

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies…

David Moadel | Apr 20, 2026 at 10:40 AM EDT

Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change…

Gerelyn Terzo | Apr 14, 2026 at 10:19 AM EDT

Live Nasdaq Composite: Markets Extend Rebound, Oil Slips in Pivot Toward Tech Deals

This article will be updated throughout the day, so check back often for more daily updates. Markets are continuing to…

Vandita Jadeja | Apr 10, 2026 at 12:09 PM EDT

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February,…

Trey Thoelcke | Apr 10, 2026 at 8:25 AM EDT

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs.…

David Beren | Apr 3, 2026 at 12:10 PM EDT

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

One of the world’s leading healthcare names, Novo Nordisk (NYSE:NVO | NVO Price Prediction) cut prices on Wegovy and Ozempic…

Michael Williams | Mar 28, 2026 at 7:15 AM EDT

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of…

David Moadel | Mar 23, 2026 at 9:34 AM EDT

NVIDIA’s Monday Rebound: What Energy Partnerships and BioNeMo Mean for NVDA Stock

NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) shares are up roughly 2% in Monday morning trading, offering a modest but welcome…

David Moadel | Mar 17, 2026 at 12:27 PM EDT

Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

Eli Lilly (NYSE:LLY | LLY Price Prediction) stock is down 5% in Tuesday afternoon trading, with shares falling to $937…

Joel South | Mar 10, 2026 at 10:23 AM EDT

Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit

Four names are drawing analyst attention this week, with TD Cowen stepping back from Novo Nordisk A/S (NYSE:NVO | NVO…

1 2 3 4 … 12

Novo Nordisk : NVO

All Novo Nordisk Articles

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Three Biotechs That Are Top Takeover Targets

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal

Live Nasdaq Composite: Markets Extend Rebound, Oil Slips in Pivot Toward Tech Deals

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

NVIDIA’s Monday Rebound: What Energy Partnerships and BioNeMo Mean for NVDA Stock

Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit

Live Nasdaq Composite: Stocks Slip as Oil Climbs, Big Tech Earnings Take Spotlight

Wall Street is Bullish on Marvell. Here’s Our Price Target.

Super Micro Just Disclosed $60 Billion in New Orders and a Massive Margin Beat

‘Inflation Is a Choice’: Cracking Fed Chair Kevin Warsh’s Code Before Next Week’s Rate Showdown

Why Spreading a $750,000 Inherited 401(k) Over 10 Years Saves $120,000 in Federal Taxes

70-Year-Old Federal Retiree With $1.1 Million Discovers One RMD Disqualified Him From the Hold-Harmless Rule

Why Spreading a $750,000 Inherited 401(k) Over 10 Years Saves $120,000 in Federal Taxes

Wall Street is Bullish on Marvell. Here’s Our Price Target.

Novo Nordisk : NVO

All Novo Nordisk Articles

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Three Biotechs That Are Top Takeover Targets

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal

Live Nasdaq Composite: Markets Extend Rebound, Oil Slips in Pivot Toward Tech Deals

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

NVIDIA’s Monday Rebound: What Energy Partnerships and BioNeMo Mean for NVDA Stock

Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit

Live Nasdaq Composite: Stocks Slip as Oil Climbs, Big Tech Earnings Take Spotlight

Wall Street is Bullish on Marvell. Here’s Our Price Target.

Super Micro Just Disclosed $60 Billion in New Orders and a Massive Margin Beat

‘Inflation Is a Choice’: Cracking Fed Chair Kevin Warsh’s Code Before Next Week’s Rate Showdown

Featured Reads

Why Spreading a $750,000 Inherited 401(k) Over 10 Years Saves $120,000 in Federal Taxes

70-Year-Old Federal Retiree With $1.1 Million Discovers One RMD Disqualified Him From the Hold-Harmless Rule